Cluster-randomised trial of community-based screening for eye disease in adults in Nepal: the Village-Integrated Eye Worker Trial II (VIEW II) trial protocol

Kieran S O'Brien, Valerie M Stevens, Raghunandan Byanju, Ram Prasad Kandel, Gopal Bhandari, Sadhan Bhandari, Jason S Melo, Travis C Porco, Thomas M Lietman, Jeremy D Keenan, Group Information for the VIEW II Study Group, Prakriti Acharaya, Manmohan Adhikari, Shree Kanta Adihikari, Deepak Bhattarai, Rabin Bhattarai, Gopal Bhandari, Sadhan Bhandari, Raghunandan Byanju, Ajaya Chaudhary, Bhagiram Chaudhary, Daya Shankar Chaudhary, Kishor Chaudhary, Krishna Raj Dharel, Maria Gautam, Shree Krishna Gautam, Aakriti Ghimire, Bishwash Ghimire, Narayan Ghimire, Ramesh Ghimire, Gaurav Giri, Puspa Giri, Dhanmaya Gurau, Ramesh Gurung, Deepak Kandel, Simanta Khadka, Benju Lamichhane, Pappu Mahato, Pratikshya Neupane, Ram Janaki Panday, Sabina Parajuli, Radhika Devi Poudel, Susmita Poudel, Sangita Pradhan, Suchan Pun, Bishaka Ranabhat, Sudha Ranabhat, Gaurav Rimal, Gopal Sapkota, Subit Sapkota, Ranjeet Shah, Manisha Shrestha, Saraswati Silwal, Amisha Subedi, Pradeep Subedi, Alish Tamang, Dilip Tandukar, Nischal Sharma Wagle, Nilam Kumari Yadav, Sailesh Mishra, Heidi Chase, Suzanne Gilbert, Lauren Jesudason, Chundak Tenzing, Shravan Chaudhary, Parami Dhakwha, Ram Prasad Kandel, Prasanna Sharma, Apsara Shrestha, Jeremy Keenan, Thomas Lietman, Jason Melo, Kieran O'Brien, Travis Porco, Daniel Schwartz, Riju Shrestha, Robert Stamper, Valerie Stevens, Kieran S O'Brien, Valerie M Stevens, Raghunandan Byanju, Ram Prasad Kandel, Gopal Bhandari, Sadhan Bhandari, Jason S Melo, Travis C Porco, Thomas M Lietman, Jeremy D Keenan, Group Information for the VIEW II Study Group, Prakriti Acharaya, Manmohan Adhikari, Shree Kanta Adihikari, Deepak Bhattarai, Rabin Bhattarai, Gopal Bhandari, Sadhan Bhandari, Raghunandan Byanju, Ajaya Chaudhary, Bhagiram Chaudhary, Daya Shankar Chaudhary, Kishor Chaudhary, Krishna Raj Dharel, Maria Gautam, Shree Krishna Gautam, Aakriti Ghimire, Bishwash Ghimire, Narayan Ghimire, Ramesh Ghimire, Gaurav Giri, Puspa Giri, Dhanmaya Gurau, Ramesh Gurung, Deepak Kandel, Simanta Khadka, Benju Lamichhane, Pappu Mahato, Pratikshya Neupane, Ram Janaki Panday, Sabina Parajuli, Radhika Devi Poudel, Susmita Poudel, Sangita Pradhan, Suchan Pun, Bishaka Ranabhat, Sudha Ranabhat, Gaurav Rimal, Gopal Sapkota, Subit Sapkota, Ranjeet Shah, Manisha Shrestha, Saraswati Silwal, Amisha Subedi, Pradeep Subedi, Alish Tamang, Dilip Tandukar, Nischal Sharma Wagle, Nilam Kumari Yadav, Sailesh Mishra, Heidi Chase, Suzanne Gilbert, Lauren Jesudason, Chundak Tenzing, Shravan Chaudhary, Parami Dhakwha, Ram Prasad Kandel, Prasanna Sharma, Apsara Shrestha, Jeremy Keenan, Thomas Lietman, Jason Melo, Kieran O'Brien, Travis Porco, Daniel Schwartz, Riju Shrestha, Robert Stamper, Valerie Stevens

Abstract

Introduction: The majority of blindness worldwide could be prevented or reversed with early diagnosis and treatment, yet identifying at-risk and prevalent cases of eye disease and linking them with care remain important obstacles to addressing this burden. Leading causes of blindness like glaucoma, diabetic retinopathy and age-related macular degeneration have detectable early asymptomatic phases and can cause irreversible vision loss. Mass screening for such diseases could reduce visual impairment at the population level.

Methods and analysis: This protocol describes a parallel-group cluster-randomised trial designed to determine whether community-based screening for glaucoma, diabetic retinopathy and age-related macular degeneration reduces population-level visual impairment in Nepal. A door-to-door population census is conducted in all study communities. All adults aged ≥60 years have visual acuity tested at the census visit, and those meeting referral criteria are referred to a local eye care facility for further diagnosis and management. Communities are subsequently randomised to a community-based screening programme or to no additional intervention. The intervention consists of a single round of screening including intraocular pressure and optical coherence tomography assessment of all adults ≥60 years old with enhanced linkage to care for participants meeting referral criteria. Four years after implementation of the intervention, masked outcome assessors conduct a repeat census to collect data on the primary outcome, visual acuity. Individuals with incident visual impairment receive a comprehensive ophthalmological examination to determine the cause of visual impairment. Outcomes are compared by treatment arm according to the originally assigned intervention.

Ethics and dissemination: The trial has received ethical approval from the University of California San Francisco Institutional Review Board, Nepal Netra Jyoti Sangh and the Nepal Health Research Council. Results of this trial will be disseminated through publication in peer-reviewed journals and presentation at local and international meetings.

Trial registration number: NCT03752840.

Keywords: age-related macular degeneration; diabetic retinopathy; glaucoma; mass screening; randomised controlled trial.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Trial flow and timeline. The randomisation unit is a group of contiguous small government demographic units (ie, toles) from the same ward, termed a study cluster. Wards are divided into study clusters after the initial census depending on the ward population; sample size calculations are approximations since baseline census activities are ongoing.

References

    1. Flaxman SR, Bourne RRA, Resnikoff S, et al. . Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health 2017;5:e1221–34. 10.1016/S2214-109X(17)30393-5
    1. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organization, 1968: 164.
    1. Tan NYQ, Friedman DS, Stalmans I, et al. . Glaucoma screening: where are we and where do we need to go? Curr Opin Ophthalmol 2020;31:91–100. 10.1097/ICU.0000000000000649
    1. Polack S, Yorston D, López-Ramos A, et al. . Rapid assessment of avoidable blindness and diabetic retinopathy in Chiapas, Mexico. Ophthalmology 2012;119:1033–40. 10.1016/j.ophtha.2011.11.002
    1. Chou R, Dana T, Bougatsos C, et al. . Screening for impaired visual acuity in older adults: updated evidence report and systematic review for the US preventive services Task force. JAMA 2016;315:915–33. 10.1001/jama.2016.0783
    1. Clarke EL, Evans JR, Smeeth L. Community screening for visual impairment in older people. Cochrane Database Syst Rev 2018;2:CD001054. 10.1002/14651858.CD001054.pub3
    1. Hernández RA, Burr JM, Vale LD, et al. . Economic evaluation of screening for open-angle glaucoma. Int J Technol Assess Health Care 2008;24:203–11. 10.1017/S0266462308080288
    1. Tay T, Rochtchina E, Mitchell P, et al. . Eye care service utilization in older people seeking aged care. Clin Exp Ophthalmol 2006;34:141–5. 10.1111/j.1442-9071.2006.01139.x
    1. Smeeth L, Fletcher AE, Hanciles S, et al. . Screening older people for impaired vision in primary care: cluster randomised trial. BMJ 2003;327:1027. 10.1136/bmj.327.7422.1027
    1. Eekhof J, De Bock G, Schaapveld K, et al. . Effects of screening for disorders among the elderly: an intervention study in general practice. Fam Pract 2000;17:329–33. 10.1093/fampra/17.4.329
    1. Moore AA, Siu AL, Partridge JM, et al. . A randomized trial of office-based screening for common problems in older persons. Am J Med 1997;102:371–8. 10.1016/S0002-9343(97)00089-2
    1. Chan A-W, Tetzlaff JM, Altman DG, et al. . Spirit 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200–7. 10.7326/0003-4819-158-3-201302050-00583
    1. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. . Spirit 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. 10.1136/bmj.e7586
    1. Pradhan S, Deshmukh A, Giri Shrestha P, et al. . Prevalence of blindness and cataract surgical coverage in Narayani zone, Nepal: a rapid assessment of avoidable blindness (RAAB) study. Br J Ophthalmol 2018;102:291–4. 10.1136/bjophthalmol-2017-310716
    1. Thapa R, Bajimaya S, Paudyal G, et al. . Prevalence of and risk factors for age-related macular degeneration in Nepal: the Bhaktapur retina study. Clin Ophthalmol 2017;11:963–72. 10.2147/OPTH.S132338
    1. Thapa R, Twyana SN, Paudyal G, et al. . Prevalence and risk factors of diabetic retinopathy among an elderly population with diabetes in Nepal: the Bhaktapur retina study. Clin Ophthalmol 2018;12:561–8. 10.2147/OPTH.S157560
    1. Thapa SS, Paudyal I, Khanal S, et al. . A population-based survey of the prevalence and types of glaucoma in Nepal: the Bhaktapur glaucoma study. Ophthalmology 2012;119:759–64. 10.1016/j.ophtha.2011.10.021
    1. Bastawrous A, Rono HK, Livingstone IAT, et al. . Development and validation of a smartphone-based visual acuity test (peek acuity) for clinical practice and community-based fieldwork. JAMA Ophthalmol 2015;133:930–7. 10.1001/jamaophthalmol.2015.1468
    1. World Health Organization Consultation on development of standards for characterization of vision loss and visual functioning : Deafness pob. Geneva: World Health Organization, 2003.
    1. Kumar RS, Rackenchath MV, Sathidevi AV, et al. . Accuracy of pinhole visual acuity at an urban Indian Hospital. Eye 2019;33:335–7. 10.1038/s41433-018-0237-6
    1. Harris PA, Taylor R, Thielke R, et al. . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81. 10.1016/j.jbi.2008.08.010
    1. McClintic SM, Prajna NV, Srinivasan M, et al. . Visual outcomes in treated bacterial keratitis: four years of prospective follow-up. Invest Ophthalmol Vis Sci 2014;55:2935–40. 10.1167/iovs.14-13980

Source: PubMed

3
구독하다